This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In this issue: The State of SpecialtyPharmacy 2021 How health plans profit—and patients lose—from insulin A fantastic new analysis of the gross-to-net bubble Reconsidering Amazon P.S. Please join the nearly 13,000 consumers of my daily commentary and links to neat stuff at @DrugChannels on Twitter. Happy Thanksgiving, everyone!
In this issue: The State of SpecialtyPharmacy 2021 How health plans profit—and patients lose—from insulin A fantastic new analysis of the gross-to-net bubble CVS acknowledges how its PBM profits from 340B Reconsidering Amazon P.S. You can also find my daily posts on LinkedIn , where I have more than 21,000 followers. to 1:30 p.m.
In this issue: The State of SpecialtyPharmacy 2021 How health plans profit—and patients lose—from insulin A fantastic new analysis of the gross-to-net bubble CVS acknowledges how its PBM profits from 340B Reconsidering Amazon Plus, the FDA preps you for Thursday with a regulatory soup review. Happy Thanksgiving, everyone!
While we all roll up our sleeves for a full reopening, let’s spring into this month’s selection of noteworthy news: Thoughts on Cigna’s payments to patients for non-medical switching 340B’s explosive specialtypharmacy growth An excellent analysis of GoodRx Plus, my $0.02 drugpricing policy. 3, and more.
Fein will share his latest thinking on a wide range of topics, including: Retail and specialtypharmacy trends Vertical integration and consolidation The Inflation Reduction Act of 2022 The Medicare Part D Redesign Biosimilars Discount cards and cash-pay pharmacies The growing impact of hospitals and health systems The 340B DrugPricing Program Federal (..)
On March 15, 2022, Drug Channels Institute will release The 2022 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers. drugpricing, reimbursement, and dispensing system. This 2022 edition addresses COVID-19 and its ongoing impact on the pharmacy and PBM industries.
In this issue: The State of SpecialtyPharmacy 2021 How health plans profit—and patients lose—from insulin A fantastic new analysis of the gross-to-net bubble CVS acknowledges how its PBM profits from 340B Reconsidering Amazon P.S. You can also find my daily posts on LinkedIn , where I have more than 21,000 followers. to 1:30 p.m.
On March 14, 2023, Drug Channels Institute will release The 2023 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers. drugpricing, reimbursement, and dispensing system. This report—our fourteenth edition—remains the most comprehensive, fact-based tool for understanding the entire U.S.
We negotiate the lowest pricing in our network of retail pharmacies, mail order pharmacy and specialtypharmacy partnerships. Excellent member experience It’s hard to lower your pharmacy costs if your members aren’t getting adequate support to follow their therapies correctly and start feeling better.
By adopting these proposals alongside the recommended enhancements, CMS can establish a transparent and equitable pharmacy network system that prioritizes patient access, supports provider sustainability, and ensures care continuity for Medicare beneficiaries.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
75 
Let's personalize your content